Brief: AB Science Says FDA Granted Status Of Minor Use In Major Species For Masivet
09/02/2026 17:36
Feb 9 (Reuters) - AB Science SA ABS.PA: AB SCIENCE ANNOUNCED THAT THE FOOD AND DRUG ADMINISTRATION (FDA) GRANTED THE STATUS OF MINOR USE IN MAJOR SPECIES (MUMS) FOR MASIVET® IN THE TREATMENT OF CANINE MAST CELL TUMORS AB SCIENCE SA: IN CASE OF MASIVET APPROVAL IN USA, CO EXPECTS EBITDA GENERATED FROM ANIMAL HEALTH TO COVER PART OF ITS FIXED-COST STRUCTURE AB SCIENCE SA: DISCUSSING DISTRIBUTION AGREEMENTS FOR NEW REGIONS NOT YET COVERED Source text: ID:nGNXbGbSd2 Further company coverage: ABS.PA ((Reuters.Briefs@thomsonreuters.com;))
Recent news on AB Science SA
See all newsBrief: AB Science Expects To Resume AB8939 Phase 1 In Q1 2027 And Masitinib Phase 3 In Q4 2027
Brief: AB Science Discontinues Phase 2 AB20006, Phase 3 AB15003, Phase 3 AB20009 Studies
Brief: AB Science Temporarily Halts Europe Clinical Trials Ahead Of Strategic Reorganization
Brief: AB Science Says FDA Granted Status Of Minor Use In Major Species For Masivet
Brief: AB Science Says Co Received Japanese Patent Protection To Use Masitinib In Progressive MS Until 2041